Press Releases White House Must Cut Prices, Expand Access to Opioid Overdose Antidote October 23, 2018
Letters, Testimony & Filings Letter to the FDA Urging the Agency Not to Approve the New Drug Application for Sufentanil Sublingual Tablets, a Super-Potent Opioid October 18, 2018
Letters, Testimony & Filings Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee Regarding Sublingual Sufentanil Tablets October 12, 2018
Commentary Outrage of the Month: Pharma’s Price Gouging Forces Rationing of Lifesaving Opioid Overdose Antidote June 1, 2018
Letters, Testimony & Filings Testimony Before the FDA’s Psychopharmacologic Drugs Advisory Committee Regarding Lofexidine March 27, 2018
Commentary Outrage of the Month: Opioid Maker Executives “No Better Than Street-Level Drug Dealers” December 1, 2017
Press Releases Trump Declares Opioid Public Health Emergency, But It Will Take More Than Tweets and Big Pharma Nominations to Save Lives October 26, 2017